英文論文 2020年度
- Hiraide S，Komine K，Sato Y，Ouchi K，Imai H，Saijo K，Takahashi M，Takahashi S，Shirota H，Takahashi M，Ishioka C. Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei. International Journal of Clinical Oncology 25. 774-781. Apr（2020）
- Imai H，Saijo K，Komine K，Yoshida Y，Sasaki K，Suzuki A，Ouchi K，Takahashi M，Takahashi S，Shirota H，Takahashi M，Ishioka C. Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients. Hindawi Journal of Oncology 2020. June 17（2020）
- Ikenoue T，Arai M，Ishioka C，Iwama T，Kaneko S，Matsubara N，Moriya Y，Nomizu T，Sugano K，Tamura K，Tomita N，Yoshida T，Sugihara K，Naruse H，Yamaguchi K，Nojima M，Nakamura Y，Furukawa Y. Correction: Importance of gastric cancer for the diagnosis and surveillance of Japanese Lynch syndrome patients. Journal of Human Genetics 65. 633. Jul（2020）
- Takahashi K，Ishibashi E，Kubo T，Harada Y，Hayashi H，Kano M，Shimizu Y，Shirota H，Mori Y，Muto M，Ishioka C，Dosaka-Akita H，Matsubara H，Nishihara H，Sueoka-Aragane N，Toyooka S，Hirakawa A，Tateishi U，Miyake S，Ikeda S. A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial). Medicine (Baltimore) 99. e21457. Aug 7（2020）
- Hayashi H，Takiguchi Y，Minami H，Akiyoshi K，Segawa Y，Ueda H，Iwamoto Y，Kondoh C，Matsumoto K，Takahashi S，Yasui H，Sawa T，Onozawa Y，Chiba Y，Togashi Y，Fujita Y，Sakai K，Tomida S，Nishio K，Nakagawa K. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. JAMA Oncol 6. 1-9. Oct 15（2020）
- Takahashi M，Kato K，Okada M，Chin K，Kadowaki S，Hamamoto Y，Doki Y，Kubota Y，Kawakami H，Ogata T，Hara H，Muto M，Nakashima Y，Ishihara R，Tsuda M，Motoyama S，Kodani M，Kitagawa Y. Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3). Esophagus 18. 90-99. Jan（2021）
- Imai H，Saijo K，Chikamatsu S，Kawamura Y，Ishioka C. LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11. Cancer Science 112. 792-802. Feb（2021）
- Hiratsuka Y，Oishi T，Miyashita M，Morita T，Mack J W，Takahashi M，Shirota H，Otsuka K，Ishioka C，Inoue A. Patients' understanding of communication about palliative care and health condition in Japanese patients with unresectable or recurrent cancer: a cross-sectional survey. Annals of Palliative Medicine Feb 7（2021）
- Hiraide S，Komine K，Takahashi M，Ishioka C. Reply to comments on "Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei". International Journal of Clinical Oncology 26. 621.Mar（2021）
